Project Grant R01AI189783
Award Date 8/22/25
Completion Date 7/31/30
Dollars Obligated $682K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
- This Project Grant award of $184,109, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research on modulating monocyte and T cell functions during subclinical malaria. The grantee, the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, will investigate the role of immune inhibitory receptors LILRB1 and LILRB2 in regulating innate and adaptive immune...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $690,500 to Boston University Medical Campus to investigate the mechanisms underlying poor immune responses to the booster dose of the RTS,S malaria vaccine in African children. The key objectives are to: 1) identify specific antibody responses and functions that are suboptimal after the booster dose; 2)...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $122,597 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Texas Health Science Center at San Antonio. The grant, which runs from January 2025 to September 2027, will support research to analyze the function and antibody-mediated inhibition of the malaria vaccine candidate PF3D7_1136200. This highly conserved Plasmodium falciparum protein is a promising...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $310,492 Project Grant under the Allergy and Infectious Diseases Research Program (CFDA 93.855) to the University of Washington. The grant, titled "Understanding and Overcoming Plasmodium-Specific Immune Evasion Mechanisms," aims to investigate how Plasmodium infection influences the pre-vaccine memory B cell pool to understand why current malaria vaccines have limited efficacy in endemic areas. The research...
- This $244,440 federal Project Grant was awarded on January 14, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant was awarded to the Albert Einstein College of Medicine in Bronx, New York to conduct research on the role of cytolytic ZEB2+ memory CD4+ T cells in providing protection against the liver stage of malaria infection. The research seeks to gain insights into the cellular immune...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $813,450 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to Case Western Reserve University. The 5-year grant, effective August 1, 2025, supports research to evaluate human T cell responses to Mycobacterium tuberculosis antigens that are processed and presented by infected macrophages. The goal is to develop a better understanding of how variation in human T cell...
- This federal Project Grant award of $708,202, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), supports research to identify targets of naturally acquired protection against severe Plasmodium falciparum malaria and develop them as novel blood-stage vaccine candidates. The award to Brown University will: 1) conduct a case-control study in Kenya to identify infants and children with severe malaria and matched controls, 2)...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $426,938 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University. The grant will fund research to explore combining human monoclonal antibodies targeting the Reticulocyte-binding protein 5 (RH5) with small molecule inhibitors to enhance efficacy and prevent drug resistance against asexual Plasmodium falciparum malaria parasites. The research aims to...
- This $412,500 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at the University of South Florida to evaluate immunodominant fragments of the PfGARP antigen for the development of a malaria vaccine. The project aims to identify smaller recombinant PfGARP fragments that can generate functional antibodies and growth inhibition activity comparable to the full-length PfGARP-A antigen. The...
- This Project Grant award of $183,276 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research on enhancing the efficacy of liver stage malaria vaccines. The funded project aims to investigate the mechanism behind the reduced CD8+ T cell responses observed in individuals with prior malaria exposure, which compromises the effectiveness of the current gold standard radiation-attenuated sporozoite (RAS) vaccine...